Emerging Immunotherapy Approaches for Treating Prostate Cancer

被引:10
|
作者
Meng, Lingbin [1 ]
Yang, Yuanquan [1 ]
Mortazavi, Amir [1 ]
Zhang, Jingsong [2 ]
机构
[1] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, 12902 USF Magnolia Dr, Tampa, FL 33612 USA
关键词
immunotherapy; prostate cancer; immune checkpoint inhibitors; bispecific antibodies; CAR T cells; vaccines; cytokines; immunotherapeutic combinations; CAR-T-CELLS; IMMUNE-CHECKPOINT; DOUBLE-BLIND; PHASE-III; PLUS DOCETAXEL; CLINICAL-TRIAL; SIPULEUCEL-T; TUMOR MICROENVIRONMENT; DNA VACCINE; ANTIGEN;
D O I
10.3390/ijms241814347
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy has emerged as an important approach for cancer treatment, but its clinical efficacy has been limited in prostate cancer compared to other malignancies. This review summarizes key immunotherapy strategies under evaluation for prostate cancer, including immune checkpoint inhibitors, bispecific T cell-engaging antibodies, chimeric antigen receptor (CAR) T cells, therapeutic vaccines, and cytokines. For each modality, the rationale stemming from preclinical studies is discussed along with outcomes from completed clinical trials and strategies to improve clinical efficacy that are being tested in ongoing clinical trials. Imperative endeavors include biomarker discovery for patient selection, deciphering resistance mechanisms, refining cellular therapies such as CAR T cells, and early-stage intervention were reviewed. These ongoing efforts instill optimism that immunotherapy may eventually deliver significant clinical benefits and expand treatment options for patients with advanced prostate cancer.
引用
收藏
页数:26
相关论文
共 50 条
  • [31] Prostate Cancer Immunotherapy
    Karan, Dev
    Van Veldhuizen, Peter
    CURRENT CANCER THERAPY REVIEWS, 2012, 8 (04) : 237 - 237
  • [32] IMMUNOTHERAPY FOR PROSTATE CANCER?
    Drake, C.
    ANNALS OF ONCOLOGY, 2014, 25
  • [33] Immunotherapy for Prostate Cancer
    Djavan, Bob
    CANADIAN JOURNAL OF UROLOGY, 2011, 18 (04) : 5763 - 5763
  • [34] Immunotherapy and prostate cancer
    Kaminski, JM
    Summers, JB
    Ward, MB
    Huber, MR
    Minev, B
    CANCER TREATMENT REVIEWS, 2003, 29 (03) : 199 - 209
  • [35] Immunotherapy for prostate cancer
    Fong L.
    Small E.J.
    Current Oncology Reports, 2007, 9 (3) : 226 - 233
  • [36] Immunotherapy of prostate cancer
    Freedland S.J.
    Pantuck A.J.
    Weider J.
    Zisman A.
    Belldegrun A.S.
    Current Urology Reports, 2001, 2 (3) : 242 - 247
  • [37] Immunotherapy in Prostate Cancer
    Fay, Emily K.
    Graff, Julie N.
    CANCERS, 2020, 12 (07) : 1 - 17
  • [38] Immunotherapy in prostate cancer
    Lekili, Murat
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (02): : 82 - 84
  • [39] Prostate cancer immunotherapy
    McNeel, Douglas G.
    CURRENT OPINION IN UROLOGY, 2007, 17 (03) : 175 - 181
  • [40] Immunotherapy for Prostate Cancer
    Venturini, Nicholas J.
    Drake, Charles G.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2019, 9 (05):